1. Scrip
  2. >>Business

NIH Study Keeps Synairgen’s Dream Of An Inhaled COVID-19 Therapy Alive

Two Readouts Expected In 2022

 
• By Andrew McConaghie

SNG001 has moved into a Phase III open label trial in which it must prove its non-inferiority against Regeneron's monoclonal antibody cocktail.

NIH
The NIH's ACTIV-2 study is focused on accelerating development of antibody treatments and other therapies for non-hospitalized COVID-19 patients. • Source: Alamy

With the pandemic far from vanquished, there is still a need for more treatment options for treating COVID-19 both in outpatient and hospital settings, and small UK biopharma company Synairgen hopes its inhaled beta-interferon therapy SNG001 could still play a role.

Monoclonal antibody combinations, especially Regeneron and Roche’s REGEN-COV (casirivimab and imdevimab), are now widely used in the US and Europe, but manufacturing and administering the

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: AstraZeneca CEO cautions Europe; Pfizer CEO optimistic on US tariffs, pricing; Merck & Co reassures on pipeline; Merck KGaA buys SpringWorks; and Akeso explains ivonescimab overall survival data.

Vertex Sinks On Below-Consensus Revenue, Limited Sales From New Launches

 
• By Mandy Jackson

Vertex is in need of diversification, but in addition to its lower-than-expected Q1 revenue, sales of the company’s newest CF drug Alyftrek and pain medicine Journavx disappointed.

Aldeyra Plans To File Reproxalap Again With New Dry Eye Symptom Data

 
• By Joseph Haas

The biotech hopes a third time will be the charm after two FDA complete responses, with plans to position its eye drop as offering quicker onset of action.